ATE353665T1 - Glp-2 enthaltende formulierungen - Google Patents

Glp-2 enthaltende formulierungen

Info

Publication number: ATE353665T1
Authority: AT; Austria
Prior art keywords: glp; formulations containing; containing glp; formulations; histidine
Prior art date: 1999-12-30

Application number

AT00988416T

Other languages

English (en)

Inventor

Indu J Isaacs

Original Assignee

Nps Allelix Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-30

Filing date

2000-12-29

Publication date

2007-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10867197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE353665(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-12-29 Application filed by Nps Allelix Corp filed Critical Nps Allelix Corp

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE353665T1 publication Critical patent/ATE353665T1/de

Links

101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 4
102400000326 Glucagon-like peptide 2 Human genes 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229960002885 histidine Drugs 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
239000008363 phosphate buffer Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT00988416T 1999-12-30 2000-12-29 Glp-2 enthaltende formulierungen ATE353665T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9930882.7A GB9930882D0 (en)	1999-12-30	1999-12-30	GLP-2 formulations

Publications (1)

Publication Number	Publication Date
ATE353665T1 true ATE353665T1 (de)	2007-03-15

Family

ID=10867197

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00988416T ATE353665T1 (de)	1999-12-30	2000-12-29	Glp-2 enthaltende formulierungen

Country Status (13)

Country	Link
US (1)	US7056886B2 (de)
EP (1)	EP1246639B1 (de)
JP (3)	JP5001498B2 (de)
AT (1)	ATE353665T1 (de)
AU (1)	AU782110B2 (de)
CA (1)	CA2395814C (de)
CY (1)	CY1106558T1 (de)
DE (1)	DE60033437T2 (de)
DK (1)	DK1246639T3 (de)
ES (1)	ES2282161T3 (de)
GB (1)	GB9930882D0 (de)
PT (1)	PT1246639E (de)
WO (1)	WO2001049314A2 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020025933A1 (en) *	1996-08-30	2002-02-28	Knudsen Liselotte Bjerre	GLP-2 derivatives
GB9930882D0 (en) *	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
US20030119734A1 (en)	2001-06-28	2003-06-26	Flink James M.	Stable formulation of modified GLP-1
WO2003099854A2 (en)	2002-05-24	2003-12-04	Nps Allelix Corp.	Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
DK2311432T3 (en) *	2002-06-07	2015-02-02	Dyax Corp	Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en) *	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
TR201900937T4 (tr) *	2002-08-28	2019-02-21	Dyax Corp	Organların ve dokuların muhafaza edilmesine yönelik yöntem.
WO2004035624A2 (en) *	2002-10-14	2004-04-29	Novo Nordisk A/S	Glucagon - like peptide - 2 variants
CN1812808B (zh) *	2003-06-03	2012-07-04	诺沃挪第克公司	稳定化的药物肽组合物
JP4936884B2 (ja) *	2003-06-03	2012-05-23	ノボ・ノルデイスク・エー／エス	安定化された薬学的ペプチド組成物
WO2004105790A1 (en) *	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
EP2107069B1 (de)	2003-08-05	2013-01-16	Novo Nordisk A/S	Neuartige Insulinderivate
US20060247167A1 (en) *	2003-09-01	2006-11-02	Novo Nordisk A/S	Stable formulations of peptides
EP1663295A2 (de) *	2003-09-01	2006-06-07	Novo Nordisk A/S	Stabilisierte peptidformulierungen
JP2007534633A (ja) *	2003-11-10	2007-11-29	アライバ−プロメティックインコーポレイティド	ヒト・アルファ１−抗トリプシン製剤
PT1687019T (pt)	2003-11-20	2018-02-26	Novo Nordisk As	Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
HRP20120315T1 (hr) *	2003-11-21	2012-05-31	Nps Pharmaceuticals	Proizvodnja peptida 2 nalik glukagonu i analoga
EP1789434B1 (de) *	2004-08-31	2013-11-20	Novo Nordisk A/S	Verwendung von tris(hydroxymethyl)-aminomethan zur stabilisierung von peptiden, polypeptiden und proteinen
US7235530B2 (en) *	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7847061B2 (en)	2004-11-01	2010-12-07	Nps Pharmaceuticals, Inc.	Treatment of short bowel syndrome patients with colon-in-continuity
EP2494983B1 (de) *	2004-11-12	2019-04-24	Novo Nordisk A/S	Stabile formulierung von glp-1
CN100418983C (zh) *	2005-05-11	2008-09-17	中国药科大学	人胰高血糖素相关肽-2类似物
PL1931350T5 (pl)	2005-09-14	2021-11-15	Takeda Pharmaceutical Company Limited	Podanie inhibitorów dipeptydylo-peptydazy
WO2007033427A1 (en) *	2005-09-23	2007-03-29	Metabolic Pharmaceuticals Limited	Stabilisation of peptides with basic amino acids
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
EP2001500A4 (de) *	2006-03-10	2010-07-28	Dyax Corp	Formulierungen für ecallantid
EP2150537A4 (de) *	2007-06-01	2010-09-22	Acologix Inc	Hochtemperaturstabile peptidformulierung
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
EP2337585A1 (de) *	2008-09-19	2011-06-29	Nektar Therapeutics	Polymerkonjugate von glp-2-artigen peptiden
KR20110085985A (ko)	2008-10-30	2011-07-27	노보 노르디스크 에이/에스	하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
US8637454B2 (en) *	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
WO2011041293A1 (en)	2009-09-30	2011-04-07	Takeda Pharmaceutical Company Limited	Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US9610329B2 (en)	2009-10-22	2017-04-04	Albireo Pharma, Inc.	Stabilized glucagon solutions
DK2490708T3 (da) *	2009-10-22	2013-04-15	Biodel Inc	Stabiliserede glucagon-opløsninger
EP2314616A1 (de) *	2009-10-23	2011-04-27	Ferring B.V.	GLP-2-Peptid-Agonisten
ES2688093T3 (es)	2010-01-06	2018-10-30	Dyax Corp.	Proteínas de unión a calicreína plasmática
WO2011097079A1 (en)	2010-02-03	2011-08-11	Takeda Pharmaceutical Company Limited	Apoptosis signal-regulating kinase 1 inhibitors
EP2611825B1 (de)	2010-08-30	2015-09-02	NPS Pharmaceuticals, Inc.	Festphasensynthese von h(gly2)glp-2
BR112013010345A2 (pt)	2010-10-27	2017-07-25	Novo Nordisk As	tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
IL269565B2 (en)	2011-01-06	2024-06-01	Dyax Corp	Plasma kallikrein binding proteins
SG194570A1 (en) *	2011-04-22	2013-12-30	Radius Health Inc	Method of drug delivery for pth, pthrp and related peptides
AU2012345768B2 (en)	2011-11-30	2016-05-12	Kindeva Drug Delivery L.P.	Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja)	2012-12-21	2016-03-03	サノフイ	二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
JP2016519127A (ja)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	新規投与レジメン
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080150B1 (de)	2013-12-13	2018-08-01	Sanofi	Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3122782A4 (de)	2014-03-27	2017-09-13	Dyax Corp.	Zusammensetzungen und verfahren zur behandlung von diabetischem makulaödem
RS67458B1 (sr)	2014-03-28	2025-12-31	Univ Duke	Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN104146969A (zh) *	2014-07-31	2014-11-19	浙江美华鼎昌医药科技有限公司	注射用或输注用比伐卢定冻干粉针制剂的制备方法
KR102676629B1 (ko)	2015-04-29	2024-06-18	래디어스 파마슈티컬스, 인코포레이티드	암을 치료하는 방법
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
AU2015416589B2 (en) *	2015-12-10	2021-04-01	Menicon Co., Ltd.	Peptide composition
BR112018011622A2 (pt)	2015-12-11	2018-11-27	Dyax Corp	método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
CN118078956A (zh) *	2016-05-06	2024-05-28	免疫新炉有限公司	用于受控和持续释放的elp融合蛋白
EP3296746A1 (de) *	2016-09-20	2018-03-21	Université de Bourgogne	In-vitro-verfahren zur diagnose eines frühstadiums von darmischämie
TWI591177B (zh)	2016-10-27	2017-07-11	中化合成生技股份有限公司	一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法
KR102881465B1 (ko)	2017-01-05	2025-11-04	래디어스 파마슈티컬스, 인코포레이티드	Rad1901-2hcl의 다형 형태
WO2018142363A1 (en) *	2017-02-06	2018-08-09	Orbicular Pharmaceutical Technologies Private Limited	Ready to use compositions of glp-2 analogues through self-administrable devices
CA3090767A1 (en)	2017-02-27	2018-08-30	Urigen N.A.	Treatment of lower urinary tract epithelium with glucagon like peptide 2
ES2894629T3 (es)	2017-06-16	2022-02-15	Zealand Pharma As	Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
HUE066356T2 (hu)	2017-08-24	2024-07-28	Novo Nordisk As	GLP-1 készítmények és alkalmazásaik
FR3072875B1 (fr) *	2017-10-31	2020-11-06	Adocia	Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019086559A1 (fr)	2017-10-31	2019-05-09	Adocia	Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3079414B1 (fr) *	2018-03-27	2020-05-01	Adocia	Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
CN112423844B (zh)	2018-07-04	2024-08-13	雷迪厄斯制药公司	Rad1901-2hcl的多晶型形式
EP3628682A1 (de)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
EP3628683A1 (de) *	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
IL281938B2 (en)	2018-10-26	2024-04-01	Novo Nordisk As	Stable semaglutide compositions and uses thereof
JOP20210218A1 (ar)	2019-02-12	2023-01-30	Radius Pharmaceuticals Inc	عمليات ومركبات
SG11202111312UA (en)	2019-06-14	2021-12-30	Zealand Pharma As	Pharmaceutical parenteral composition of dual glp1/2 agonist
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
CN121197633A (zh)	2019-12-13	2025-12-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
CA3167336A1 (en)	2020-01-13	2021-07-22	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
PE20221575A1 (es) *	2020-02-18	2022-10-06	Novo Nordisk As	Formulaciones farmaceuticas
CA3179472A1 (en) *	2020-05-22	2021-11-25	Sung Hee Hong	Liquid formulation of long-acting conjugate of glp-2
KR20230038187A (ko)	2020-06-09	2023-03-17	벡티브바이오 에이지	아프라글루타이드의 제조, 제형화 및 투여

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63307827A (ja) *	1987-06-08	1988-12-15	Kitasato Inst:The	安定化された生ウイルスワクチンおよびその製造法
US5997856A (en) *	1988-10-05	1999-12-07	Chiron Corporation	Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5652216A (en) *	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
CA2226575C (en) *	1995-07-27	2011-10-18	Genentech, Inc.	Stabile isotonic lyophilized protein formulation
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP0906338B1 (de) *	1996-04-12	2002-11-06	1149336 Ontario Inc.	Analoge des glucagon ähnlichen peptides -2
TW518219B (en) *	1996-04-26	2003-01-21	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
ATE358682T1 (de) *	1996-12-13	2007-04-15	Allelix Biopharma	Klonierte rezeptoren des glukagon-ähnlichen peptids-2
JP2002504527A (ja) *	1998-02-27	2002-02-12	ノボノルディスクアクティーゼルスカブ	部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
GB9930882D0 (en) *	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations

1999
- 1999-12-30 GB GBGB9930882.7A patent/GB9930882D0/en not_active Ceased
2000
- 2000-12-29 JP JP2001549681A patent/JP5001498B2/ja not_active Expired - Lifetime
- 2000-12-29 AT AT00988416T patent/ATE353665T1/de active
- 2000-12-29 DK DK00988416T patent/DK1246639T3/da active
- 2000-12-29 AU AU24626/01A patent/AU782110B2/en not_active Expired
- 2000-12-29 US US09/750,022 patent/US7056886B2/en not_active Expired - Lifetime
- 2000-12-29 CA CA2395814A patent/CA2395814C/en not_active Expired - Lifetime
- 2000-12-29 DE DE60033437T patent/DE60033437T2/de not_active Expired - Lifetime
- 2000-12-29 EP EP00988416A patent/EP1246639B1/de not_active Expired - Lifetime
- 2000-12-29 ES ES00988416T patent/ES2282161T3/es not_active Expired - Lifetime
- 2000-12-29 PT PT00988416T patent/PT1246639E/pt unknown
- 2000-12-29 WO PCT/US2000/035512 patent/WO2001049314A2/en not_active Ceased
2007
- 2007-05-04 CY CY20071100588T patent/CY1106558T1/el unknown
2012
- 2012-02-10 JP JP2012027323A patent/JP5604463B2/ja not_active Expired - Lifetime
2014
- 2014-05-07 JP JP2014095701A patent/JP5934739B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2395814A1 (en)	2001-07-12
US20010027180A1 (en)	2001-10-04
CA2395814C (en)	2011-09-20
EP1246639A2 (de)	2002-10-09
JP2014159463A (ja)	2014-09-04
ES2282161T3 (es)	2007-10-16
CY1106558T1 (el)	2012-01-25
WO2001049314A2 (en)	2001-07-12
GB9930882D0 (en)	2000-02-23
JP5604463B2 (ja)	2014-10-08
JP2003519195A (ja)	2003-06-17
PT1246639E (pt)	2007-05-31
AU782110B2 (en)	2005-07-07
US7056886B2 (en)	2006-06-06
JP5934739B2 (ja)	2016-06-15
WO2001049314A3 (en)	2002-01-03
EP1246639B1 (de)	2007-02-14
JP5001498B2 (ja)	2012-08-15
AU2462601A (en)	2001-07-16
DE60033437D1 (de)	2007-03-29
JP2012116861A (ja)	2012-06-21
DE60033437T2 (de)	2007-11-29
DK1246639T3 (da)	2007-06-11

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1246639

Country of ref document: EP

Publication	Publication Date	Title
DE60033437D1 (de)	2007-03-29	Glp-2 enthaltende formulierungen
DK0758248T3 (da)	2003-10-27	Formuleringer til faktor IX
EA200100519A1 (ru)	2002-02-28	Композиции на основе тонкоизмельченного эплеренона
DE69729786D1 (de)	2004-08-12	Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
BR0109943A (pt)	2003-05-27	Composições farmacêuticas
CO5700784A2 (es)	2006-11-30	Polipeptidos de virus de papiloma humano y composiciones in- munogenas
ZA981031B (en)	1998-08-11	Methods for producing dired storage-stable platelets and compositions obtained thereby
PT921812E (pt)	2002-04-29	Preparacoes de insulina contendo um halogenuro
JO2034B1 (en)	1999-05-15	Isotopes of the hormone peptide its uses and the chemical compounds it contains
BR9810495A (pt)	2000-09-12	Composição farmacêutica
ATE288893T1 (de)	2005-02-15	Polymorphe form von atorvastatin-calcium
ES2181010T3 (es)	2003-02-16	Formulaciones aproticas polares no acuosas de peptidos.
NO5775A (no)	1995-03-22	Doseringsform for krystallinsk amifostin
ATE208621T1 (de)	2001-11-15	Stabilisierung der prostaglandinzusammensetzungen
DE69417252D1 (de)	1999-04-22	Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE69508837D1 (de)	1999-05-12	Protein enthaltende stabilisierte Formulierung und Dosierungskit
ATE218581T1 (de)	2002-06-15	Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
BG99177A (bg)	1995-07-28	Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
TR199902034T2 (xx)	1999-11-22	Haricen kullan�m i�in nimes�lid jel sistemleri.
DZ2503A1 (fr)	2005-01-25	Formulation pure injectable d'un composé anesthésique.
BR0111678A (pt)	2003-06-03	Composições medicinais contendo derivados de propenona
BG66082B1 (bg)	2011-03-31	Стабилизирани интерферонови състави
AR020106A1 (es)	2002-04-10	Variantes estabilizadas del inhibidor de la subtilisina de streptomyces, gen mutante que la codifica y composicion que comprende dicha variante
DK1279677T3 (da)	2007-05-07	GD3-mimetiske peptider
DK1250337T3 (da)	2009-03-30	Substituerede homopiperidinylbenzimidazol-analoger som fundus-relaksanter